Published medical guidelines influence treatment practices and can drive clinical adoption of emerging technologies designed to improve the treatment of serious or life-threatening diseases SAN DIEGO , Jan. 30, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
Study focuses on Resistance Mechanisms in Non-Small Cell Lung Cancer; Data Expected to Further Support the Clinical Utility of Biocept's Liquid Biopsy Technology
SAN DIEGO , Jan. 25, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based biomarkers to improve the detection and treatment of cancer, announces that President and CEO Michael W.
Expansion of Biocept's EmpowerTC™ offering now includes predictive and prognostic biomarker testing to aid pathologists and urologists in the management of patients diagnosed with prostate cancer SAN DIEGO , March 26, 2019 /PRNewswire/ -- Biocept, Inc.
Expands Company's patent portfolio and marks another step in pursuit of worldwide intellectual property protection for proprietary Primer-Switch technology used to detect rare events such as cancer biomarkers found in tissue and liquid biopsies SAN DIEGO , Aug.
Biocept expands intellectual property position to 32 issued patents globally for its highly sensitive methods for detecting cancer biomarkers in blood and other specimen types SAN DIEGO , March 18, 2019 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
Expands the Company's global patent estate for the capture and detection of rare cells of interest, including CTCs shed by solid tumors, in blood and other biofluids SAN DIEGO , Sept. 24, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests
